Abstract 12P
Background
Although cancer is the second leading cause of death in the world, many cancer types including breast cancer, cervical cancer, lung cancer, and colorectal cancer can be efficiently treated if detected in their early stages, thus offering increased survival rates. Because of the ability of reflection from tumor tissue origin and systemic host response, plasma cell-free RNA (cfRNA) emerges as a highlight candidate. Previous studies have shown that plasma circulating tumor DNA (ctDNA) can serve as a potential biomarker for early detection of cancer. However, ctDNA-based assays demonstrated low sensitivity for the detection of breast cancer due to the low fraction and molecular heterogeneity of ctDNA. Unlike ctDNA, plasma cfRNA is released from the tumor microenvironment into circulation not only via cell death but also through cell-cell communication mechanisms. Cell-free mRNA (cfmRNA) is a subtype of cfRNA and its expression has been shown to reflect the transcriptomic alterations not only in tumor cells but also in other cell types in tumor microenvironments. Therefore, cfmRNAs have emerged as potential biomarkers for the early detection of breast cancer.
Methods
Here, we comprehensively profiled the cfmRNA transcriptome of breast cancer patients (n=24) and healthy individuals (n=33) by next-generation sequencing and identified differentially expressed cfmRNAs (DEM) by Deseq2. We further performed pathway enrichment analysis by the profiler, thus confirming their functional contribution to breast tumorigenesis.
Results
We found the set of 10955 DEMs, including breast-cancer markers like LAMP3, HSD11B1, PRTG, LPL, and identified 49 significantly enriched pathways. Interestingly, we discovered some DEMs (CD3D, CD8B, CD274, CTLA4, FOXP3, IL2RA) related to the distribution and function of tumor-infiltrating lymphocytes. Importantly, we demonstrated that the combination of tumor-specific and lymphocyte-related DEMs could differentiate blood samples of breast cancer patients and those of healthy individuals.
Conclusions
Our findings provide implications for the clinical utility of cfmRNAs for early detection of cancer types shedding low amounts of ctDNA such as breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh, Vietnam.
Funding
Gene Solutions Joint Stock Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract